Meeting
2022 ASCO Annual Meeting
Efficacy and safety of eribulin in the treatment of advanced adult soft tissue sarcoma (STS): First real-world data in Chinese population.
Authors
Xi Guo
Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
Xi Guo , Yuhong Zhou , Rongyuan Zhuang , Yang You , Chenlu Zhang , Zhiming Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 11577)
DOI
10.1200/JCO.2022.40.16_suppl.11577
Abstract #
11577
Poster Bd #
481
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy and safety of SY-3505, a third-generation ALK TKI, in ALK-positive advanced non-small cell lung cancer: Results from a phase I/II, multi-center study.
First Author: Yuankai Shi
Poster
2019 Gastrointestinal Cancers Symposium
Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: A pooled analysis from three phase I studies.
First Author: Aaron C. Tan
Poster
2024 ASCO Gastrointestinal Cancers Symposium
ZSAB-TOP: A phase 2 trial of tislelizumab (TIS) and ociperlimab (OCI) combined with gemcitabine and cisplatin (GemCis) as the first-line treatment for advanced biliary tract cancer (BTC).
First Author: Jia Fan
Poster
2023 ASCO Breakthrough
Efficacy and safety of pembrolizumab in advanced neuroendocrine tumors (NETs): A meta-analysis of clinical trials.
First Author: Akshit Chitkara